Article
Icotinib alone or with bevacizumab as first-line therapy in Chinese patients with advanced nonsquamous non-small cell lung cancer and activating EGFR mutations: A retrospective study.
Thoracic cancer - 1 Sept 2021
Jiang Zhansheng, Zhang Jing, Sun Haiyan, Wang Cong, Zhang Yu, Li Yanyang, Pan Zhanyu
Abstract excerpt
BACKGROUND: This study focused on comparing the safety and therapeutic effects between icotinib monotherapy and icotinib plus bevacizumab combined therapy in non-small cell lung cancer (NSCLC) cases harboring EGFR mutations. METHODS: Data were collected retrospectively from the Cancer Institute and Hospital of Tianjin Medical University between October 2018 and December 2019, where the NSCLC cases that harbored...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.